Metagenomi Therapeutics, Inc.
- MGX ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Emeryville, CA
- 119 employees
- CIK 0001785279
Updated from SEC filings through
Top things to know
Executives
-
Jian Irish President and Chief Executive Officer 10-K, 2026-03-05 - Pamela Wapnick Chief Financial Officer 4, 2026-09-10
-
Pamela Wapnick, M.B.A. Chief Financial Officer DEF 14A, 2026-04-27 -
Matthew L. Wein, J.D. General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary DEF 14A, 2026-04-27
Metagenomi Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Emeryville, CA. It trades as MGX on Nasdaq. Revenue was $25.2M in the fiscal year ending December 31, 2025, -51.8% from the year before. It reported about 119 employees. Jian Irish is President and Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $25.2M 10-K, 2026-03-05 | $52.3M 10-K, 2026-03-05 | $44.8M 10-K, 2025-03-17 |
| Operating income | -$96.0M 10-K, 2026-03-05 | -$88.9M 10-K, 2026-03-05 | -$78.5M 10-K, 2025-03-17 |
| SG&A | $26.8M 10-K, 2026-03-05 | $32.0M 10-K, 2026-03-05 | $28.8M 10-K, 2025-03-17 |
| Net income | -$87.9M 10-K, 2026-03-05 | -$78.1M 10-K, 2026-03-05 | -$68.3M 10-K, 2025-03-17 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jian Irish, Ph.D., M.B.A. | Board member (per proxy) bio: President and Chief Executive Officer | DEF 14A, 2026-04-27 |
| Jian Irish | President and Chief Executive Officer | 10-K, 2026-03-05 |
| Pamela Wapnick | Chief Financial Officer | 4, 2026-09-10 |
| Pamela Wapnick, M.B.A. | Named in proxy bio: Chief Financial Officer | DEF 14A, 2026-04-27 |
| Matthew L. Wein, J.D. | Named in proxy bio: General Counsel, Compliance Officer, Head of BD&L and Corporate Secretary | DEF 14A, 2026-04-27 |
| Eric Bjerkholt, M.B.A. | Class II Directors | 8-K, 2026-06-10 |
| Juergen Eckhardt, M.D., M.B.A. | Class II Directors | 8-K, 2026-06-10 |
| Willard H. Dere, M.D. | Board member (per proxy) bio: Chairman of the Board | DEF 14A, 2026-04-27 |
 Willard Dere | Director, Chairman of the Board | 10-K, 2026-03-05 |
| Brian C. Thomas | Director | 10-K, 2026-03-05 |
| Eric Bjerkholt | Director | 10-K, 2026-03-05 |
| Juergen Eckhardt | Director | 10-K, 2026-03-05 |
| Laurence Reid | Director | 10-K, 2026-03-05 |
What Metagenomi Therapeutics, Inc. does
We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 37.8 million (as of August 6, 2026) | 10-Q, August 10, 2026 |
|---|---|---|
| Public float | $50.9M (as of June 30, 2025) | 10-K, March 5, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 10, 2026 |
| Latest proxy statement | Meeting April 21, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | PricewaterhouseCoopers LLP (San Jose, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 9, 2026 | Laurence Reid Director | Buy | 20,000 | $23K | Form 4, September 11, 2026 |
| September 8, 2026 | Matthew Wein See Remarks | Sale | 358 | $415.28 | Form 4, September 10, 2026 |
| September 8, 2026 | Jian Irish See Remarks | Sale | 2,140 | $2K | Form 4, September 10, 2026 |
| September 8, 2026 | Pamela Wapnick Chief Financial Officer | Sale | 1,911 | $2K | Form 4, September 10, 2026 |
| June 5, 2026 | Pamela Wapnick Chief Financial Officer | Sale | 2,884 | $4K | Form 4, June 10, 2026 |
| June 5, 2026 | Jian Irish See Remarks | Sale | 3,737 | $5K | Form 4, June 10, 2026 |
| June 5, 2026 | Matthew Wein See Remarks | Sale | 558 | $725.4 | Form 4, June 10, 2026 |
| March 5, 2026 | Pamela Wapnick Chief Financial Officer | Sale | 1,581 | $3K | Form 4, March 9, 2026 |
Recent 8-K events
- 8-K filed 2026-09-22
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-11
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-03-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-10-01
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- 8-K filed 2025-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-06-11
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Metagenomi Therapeutics, Inc.
- What does Metagenomi Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are an in vivo genome editing company capitalizing on our proprietary technologies to create curative genetic medicines for patients. We were founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel gene editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. We leverage machine learning and artificial intelligence to enhance our signature gene editing systems."
- What is Metagenomi Therapeutics, Inc.'s revenue?
- $25.2M for the fiscal year ending December 31, 2025, from its 10-K filed March 5, 2026.
- Is Metagenomi Therapeutics, Inc. profitable?
- Metagenomi Therapeutics, Inc. reported net income of -$87.9M for the fiscal year ending December 31, 2025.
- How many employees does Metagenomi Therapeutics, Inc. have?
- About 119 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Metagenomi Therapeutics, Inc.?
- Jian Irish, President and Chief Executive Officer, as named in a 10-K filed March 5, 2026.
- Who is the CFO of Metagenomi Therapeutics, Inc.?
- Pamela Wapnick, Chief Financial Officer, as named in a 4 filed September 10, 2026.
- Where is Metagenomi Therapeutics, Inc. headquartered?
- Emeryville, CA.
- What is Metagenomi Therapeutics, Inc.'s stock ticker?
- MGX on Nasdaq.
- What industry is Metagenomi Therapeutics, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Metagenomi Therapeutics, Inc.'s website?
- metagenomi.co.
- When does Metagenomi Therapeutics, Inc. report earnings next?
- November 10, 2026. Source: pg_future_events.
- Is Metagenomi Therapeutics, Inc. a public company?
- Yes. Metagenomi Therapeutics, Inc. files with the SEC under CIK 0001785279 and trades as MGX.
- Who audits Metagenomi Therapeutics, Inc.?
- PricewaterhouseCoopers LLP, San Jose, California, as named in its latest annual report (10-K).
- How many shares of Metagenomi Therapeutics, Inc. are outstanding?
- 37.8 million shares as of August 6, 2026, from its 10-Q filed August 10, 2026.
- What is Metagenomi Therapeutics, Inc.'s public float?
- $50.9M as of June 30, 2025, as reported on the cover of its 10-K filed March 5, 2026.
- How many business segments does Metagenomi Therapeutics, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 10, 2026.
- When is Metagenomi Therapeutics, Inc.'s annual shareholder meeting?
- April 21, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have Metagenomi Therapeutics, Inc. insiders traded stock recently?
- Since September 5, 2025, officers and directors reported 17 open-market sales worth about $44K and 1 purchase worth about $23K on Forms 4 and 5. The most recent: Laurence Reid (Director) bought 20,000 shares on September 9, 2026.